For decades, scientists believed they understood the front door that influenza uses to break into the human body. A new study out of the University of Vermont says that assumption was wrong, and the correction could matter for every Granite Stater who has ever spent a February week flattened by the flu.
As New Hampshire Public Radio reported, researchers at UVM’s Larner College of Medicine have discovered that the two most common flu strains circulating each winter do not infect human cells the same way. The finding, published in the Journal of Virology, reorders a foundational piece of flu biology and points toward treatments that could one day be more precise and carry fewer side effects.
This is regional news with national weight. New Hampshire and the rest of New England just came out of a second consecutive brutal flu season, and the research was conducted barely across the Connecticut River. The science is early, but the implications reach directly into the doctor’s offices, school nurse stations, and senior centers where the flu does its damage every year.
The Pirate Ship Problem
Dr. Emily Bruce, an assistant professor of microbiology and molecular genetics who led the work, has a memorable way of explaining how viruses operate. She tells her own children that viruses are like pirates with no ship of their own. To get anywhere and do anything, they have to hijack someone else’s vessel. In this analogy, the human cell is the ship.
That image captures the central vulnerability of any virus. Influenza cannot replicate on its own. It lacks the biological machinery to copy itself, so it must force its way inside a host cell, commandeer that cell’s internal equipment, manufacture copies of itself, and then break out to find the next cell. The cycle repeats, cell after cell. The misery people feel, the fever, the congestion, the aches, is largely the body’s immune system counterattacking with white blood cells and antibodies as that hijacking spreads.
The key question Bruce and her team set out to answer was deceptively simple. How exactly does the virus get in the door in the first place?
The Lock That Was Not Universal
Bruce describes viral entry as a lock-and-key system. A virus carries a “key” on its outer surface, and it can only enter a cell that has the matching “lock.” Whether a given virus can infect a given cell often comes down to whether that key finds its lock.
For a long time, scientists operated on the belief that most human cells carried a single broadly used lock, a molecule called a sialic acid, and that many different flu viruses used that same general entry point. It was a tidy theory. It was also, according to the new research, incomplete.
Bruce’s team studied the two influenza A subtypes that dominate human flu seasons: H1N1 and H3N2. What they found surprised them. The two strains do not enter cells the same way. H3N2 viruses, it turns out, require something more specific than sialic acid to break in.
“That was really surprising to us because we were operating under the assumption that all of the influenza viruses went in the same way,” Bruce told NHPR. “The data we have now shows that it is some specific receptor that is being used by one of those two kinds of flu that circulate every year.”
In plain terms, one of the two seasonal flu families appears to use a specialized, narrower entry point that scientists had not pinned down. That changes the map.
Why a Narrower Door Could Be Good News
A more specific entry mechanism is not just an academic curiosity. It could be a target.
Bruce explained the difficulty with the old model. Because sialic acids sit on the surface of so many different cells and are expressed so broadly throughout the body, trying to block that entry step is like trying to lock every door in a city at once. Anything that interfered with sialic acid would likely interfere with countless normal functions, producing side effects.
But if H3N2 viruses slip in through a very specific receptor, that receptor becomes a far more attractive thing to block. A drug aimed at a narrow, specialized target could potentially stop the virus without disrupting the broad machinery of healthy cells.
“If it turns out that these H3N2 viruses enter through a very specific mechanism, it’s possible that maybe that thing is something that you can target with a drug without as many side effects,” Bruce said, “or maybe it leads to some other piece of information that we don’t understand yet that lets us design a better strategy.”
The next step for her lab is to identify the exact molecule that H3N2 needs to hijack a cell. That is the piece still missing, and finding it is the difference between an intriguing observation and an actionable drug target.
What It Means for New Hampshire
Bruce was careful to temper expectations. This is basic science, the foundational kind that comes years before anything reaches a pharmacy shelf. More research is needed before any of it changes how a doctor in Manchester or Berlin treats a sick patient. No one should expect a new flu drug next winter because of this paper.
Still, the context makes the work resonate. New Hampshire endured a rough flu season for the second year running, the kind that fills urgent care waiting rooms and empties classrooms. The annual flu vaccine remains the best available defense, but its effectiveness varies year to year depending on how well it matches the circulating strains. A treatment or preventive approach built around how the virus actually enters cells, rather than how scientists assumed it did, could eventually add a more durable tool to that defense.
The discovery also underscores how much of the science that shapes New Hampshire’s public health happens right next door. The Connecticut River valley is dotted with research institutions whose work routinely crosses state lines. New Hampshire’s own universities have produced research with national reach on everything from the state’s struggling moose population to environmental and health questions tied to federal policy shifts. Health policy debates in the region, including recurring fights over vaccine exemptions and requirements, play out against a backdrop of exactly this kind of laboratory work.
For now, the takeaway is modest but real. A long-held belief about a virus that touches nearly every household has been corrected, and the correction points toward a smarter line of attack. In a field where progress is measured in incremental discoveries, rewriting a foundational assumption is the kind of step that future treatments are built on.
Frequently Asked Questions
What did the University of Vermont flu study actually find?
Researchers led by Dr. Emily Bruce found that the two most common seasonal flu strains, H1N1 and H3N2, do not infect human cells the same way. H3N2 viruses require a more specific molecule to enter cells than the broadly used sialic acid that scientists previously assumed most flu viruses relied on.
Why does the way a virus enters cells matter?
Viral entry is the first step of infection. If scientists can block that step, they can stop the virus before it replicates. A more specific entry point is easier to target with a drug without disrupting healthy cells, which could mean treatments with fewer side effects.
Will this lead to a new flu drug soon?
Not in the near term. This is basic research, and Bruce emphasized that much more study is needed before it changes clinical care. The next step is identifying the exact molecule H3N2 uses to enter cells.
Should New Hampshire residents still get a flu shot?
Yes. The annual flu vaccine remains the most effective available protection against influenza. This research does not change current recommendations and points to possibilities years down the road, not a replacement for existing prevention.
Why is Vermont research relevant to New Hampshire?
The University of Vermont sits just across the Connecticut River, and New England research institutions routinely produce science that affects the entire region. A second straight severe flu season hit New Hampshire and Vermont alike, making advances in flu biology directly relevant to Granite State public health.
